Leerink lifts its price target on Outperform-rated Heron Therapeutics (Nasdaq: HRTX) from $38 to $57 after the company announced positive ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change FDA

Heron Therapeutics' (HRTX) Price Target Raised to $54 at BofA/Merrill LynchSeptember 23, 2015 1:25 PM Brean Capital Raises Price Target on Heron Therapeutics (HRTX) Following Positive HTX-011 Results September 23, 2015 11:00 AM Heron Therapeutics (HRTX) PT Lifted to $58 at Jefferies Following Positive DataSeptember 23, 2015 6:46 AM Form 8-K HERON THERAPEUTICS, INC. For: Sep 22September 23, 2015 6:03 AM Market Wrap: Commodities Weigh on Markets; Home Price Gains Outpaced in July; Splitsville for AshlandSeptember 22, 2015 5:23 PM Heron Therapeutics (HRTX) Announces HTX-011 Phase 2 Met Primary, Secondary Endpoints in Post-Operative PainSeptember 22, 2015 4:07 PM